<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gajbhiye, Kavita Rai</style></author><author><style face="normal" font="default" size="100%">Gajbhiye, Virendra</style></author><author><style face="normal" font="default" size="100%">Siddiqui, Imtiaz A.</style></author><author><style face="normal" font="default" size="100%">Gajbhiye, Jayant M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">cRGD functionalized nanocarriers for targeted delivery of bioactives</style></title><secondary-title><style face="normal" font="default" size="100%">Journal of Drug Targeting</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">alpha(v)beta(3) integrin receptors</style></keyword><keyword><style  face="normal" font="default" size="100%">cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">cRGD</style></keyword><keyword><style  face="normal" font="default" size="100%">nanocarriers</style></keyword><keyword><style  face="normal" font="default" size="100%">targeting</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2019</style></year><pub-dates><date><style  face="normal" font="default" size="100%">FEB</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">27</style></volume><pages><style face="normal" font="default" size="100%">111-124</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The integrins αvβ3 play a very imperative role in angiogenesis and are overexpressed in endothelial cells of the tumor. Recent years have witnessed huge exploration in the field of αvβ3 integrin-mediated bioactive targeting for treatment of cancer. In these studies, the cRGD peptide has been employed extensively owing to their binding capacity to the αvβ3 integrin. Principally, RGD-based approaches comprise of antagonist molecules of the RGD sequence, drug-RGD conjugates, and most importantly tethering of the nanocarrier surface with the RGD peptide as targeting ligand. Targeting tumor vasculature or cells via cRGD conjugated nanocarriers have emerged as a promising technique for delivering chemotherapeutic drugs and imaging agents for cancer theranostics. In this review, primary emphasis has been given on the application of cRGD-anchored nanocarriers for targeted delivery of drugs, imaging agents, etc. for tumor therapy.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><work-type><style face="normal" font="default" size="100%">Article</style></work-type><custom3><style face="normal" font="default" size="100%">&lt;p&gt;Foreign&lt;/p&gt;
</style></custom3><custom4><style face="normal" font="default" size="100%">&lt;p&gt;3.068&lt;/p&gt;
</style></custom4></record></records></xml>